Incremental Value of Implantable Cardiac Device Diagnostic Variables Over Clinical Parameters to Predict Mortality in Patients With Mild to Moderate Heart Failure

Jaimie Manlucu, MD; Vinod Sharma, PhD; Jodi Koehler, MS; Eduardo N. Warman, PhD; George A. Wells, PhD; Lorne J. Gula, MD, MPH; Raymond Yee, MD; Anthony S. Tang, MD

Background—Heart failure remains a leading cause of morbidity and mortality. Clinical prediction models provide suboptimal estimates of mortality in this population. We sought to determine the incremental value of implantable device diagnostics over clinical prediction models for mortality.

Methods and Results—RAFT (Resynchronization/Defibrillation for Ambulatory Heart Failure Trial) patients with implanted devices capable of device diagnostic monitoring were included, and demographic and clinical parameters were used to compute Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) heart failure risk scores. Patients were classified according to MAGGIC score into low (0–16), intermediate (17–24), or high (>24) risk groups. Mortality was evaluated from 6 months postimplant in accordance with the RAFT protocol. In a subset of 1036 patients, multivariable analysis revealed that intermediate and high MAGGIC scores, fluid index, atrial fibrillation, and low activity flags were independent predictors of mortality. A device-integrated diagnostic parameter that included a fluid index flag and either a positive atrial fibrillation flag or a positive activity flag was able to significantly differentiate higher from lower risk for mortality in the intermediate MAGGIC cohort. The effect was more pronounced in the high-risk MAGGIC cohort, in which device-integrated diagnostic–positive patients had a shorter time to death than those who were device-integrated diagnostic negative.

Conclusions—Device diagnostics using a combination of fluid index trends, atrial fibrillation burden, and patient activity provide significant incremental prognostic value over clinical heart failure prediction scores in higher-risk patients. This suggests that combining clinical and device diagnostic parameters may lead to models with better predictive power. Whether this risk is modifiable with early medical intervention would warrant further studies.

 Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00251251. (J Am Heart Assoc. 2019;8:e010998. DOI: 10.1161/JAHA.118.010998.)

Key Words: device diagnostics • heart failure • implantable cardioverter-defibrillator • model • mortality • prognostic factor

Heart failure (HF) remains a leading cause of morbidity and mortality, affecting 23 million people worldwide. In contrast to other forms of cardiovascular conditions, its prevalence and mortality rates continue to increase. Almost 50% of patients with HF will die within 5 years of diagnosis, and up to 40% of patients die within 1 year of hospitalization.1,2 A reliable means of identifying vulnerable patients at higher risk may help identify those in need of closer monitoring and more immediate medical attention. Several clinical prediction models have been developed to help stratify risk in patients with HF. Unfortunately, many of them have poor to modest discrimination and inconsistent performance in the greater HF population. This may partly be attributed to the evolution of HF management over time and the fact that many of these models were derived from patient cohorts recruited >20 years ago.3,4 Among the more contemporary models is the recently derived Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) HF prediction score.4 It is based on the largest available database and, unlike many of its predecessors, incorporates both preserved and reduced ejection fraction. Although it is among the most comprehensive and generalizable in the
Device Diagnostics for HF Prediction  

**Clinical Perspective**

**What Is New?**

- Heart failure (HF) clinical prediction models provide suboptimal estimates of mortality risk when used in isolation.
- Many patients with HF have therapeutic implantable cardiac devices that can provide a wealth of diagnostic data.
- In this substudy of RAFT (Resynchronization/Defibrillation for Ambulatory Heart Failure Trial), we showed that device diagnostic data, including abnormal fluid index, low activity levels, and atrial fibrillation, provided incremental prognostic value to a validated clinical HF prediction model.

**What Are the Clinical Implications?**

- In patients with implantable electronic cardiac devices, the combination of clinical prediction models and device diagnostic parameters may help improve risk stratification in the high-risk population with HF.
- This may facilitate the identification and more timely intervention on patients with HF who are at highest risk of death.

Available literature, the model calibration is not perfect in isolation.4,5

Implantable cardiac devices with diagnostic features in patients with HF have provided an alternative means of monitoring and evaluating these patients. Diagnostic physiologic parameters collected by implantable devices (eg, night heart rate, activity, atrial fibrillation [AF] burden, and intrathoracic impedance) have been shown to correlate with adverse clinical events, such as HF hospitalizations.6–11 A model combining various device diagnostic parameters further improves on the predictive power of individual device parameters,12,13 with some evidence correlating these measurements with the risk of death.14,15 Although clinical parameters and device diagnostics have been separately investigated for risk prediction models, the combined clinical utility of clinical and device diagnostic parameters has yet to be studied. In this study, we sought to determine the incremental value of implantable device diagnostics over a well-validated clinical prediction model of mortality risk in patients with mild to moderate systolic HF.

**Methods**

**Study Population**

A retrospective analysis of device and clinical data was performed on the RAFT (Resynchronization/Defibrillation for Ambulatory Heart Failure Trial) patient cohort. RAFT was a multicenter randomized controlled trial comparing implantable cardioverter-defibrillator (ICD) versus cardiac resynchronization-therapy–ICD in patients with mild to moderate HF (New York Heart Association class II–III), left ventricular systolic dysfunction (ejection fraction ≤30%), and wide QRS (≥120 ms). The rationale, design, and outcomes of this study have been published previously16,17 and complied with the Declaration of Helsinki. This study was also approved by an institutional review committee, and all subjects gave written informed consent to participate in the study. The data that support the findings of this study are available from the corresponding author on reasonable request.

To summarize, RAFT, a total of 1798 patients were enrolled at 34 centers from January 2003 through February 2009. The average age was 66±9.4 years, 82.9% were men, 67.0% had ischemic heart disease, and 80.0% had New York Heart Association class II functional capacity with an average left ventricular ejection fraction of 22.6±5.3%. Over a mean follow-up duration of 40 months, a total of 422 patients (23.5%) died; 292 deaths (16.2%) were attributable to cardiovascular causes.

Of the 1798 study participants, those implanted with a device capable of device diagnostic monitoring with >180 days of follow-up were included in this analysis. Baseline demographic and laboratory data required to calculate the MAGGIC HF prediction score were collected for each patient (Figure 1). Patients were then classified according to their MAGGIC score into low (0–16), intermediate (17–24), or high (>24) risk groups. Mortality was evaluated from 6 months postimplant forward and determined in accordance with the RAFT protocol.16

**Device Diagnostic Parameters**

The devices included in the analysis had the following 6 diagnostic parameters available: activity, AF burden, night heart rate, ICD shock, percentage biventricular pacing, and fluid index (FI). These parameters were associated with a defined “flag” that is triggered when a parameter exceeds a threshold value. A parameter is flagged when it reaches an abnormal range that is associated with worsening status of the patient. The flags for these parameters are as follows: activity flag defined as a mean activity <60 min/d for ≥1 week detected by the device’s piezoelectric sensor, AF flag defined as ≥6 hours of AF on at least 1 day, ventricular rate flag defined as ventricular rate >100 beats per minute and AF ≥6 hours for ≥1 day, night heart rate flag defined as any 7 consecutive days with average night heart rate (midnight to 4 AM) >85 beats per minute, shock flag defined as any ICD shock, ventricular pace flag defined as a mean percentage biventricular pacing <90% for patients with cardiac resynchronization therapy defibrillator, and FI flag defined as >14 days above intrathoracic impedance threshold.
determined from the impedance measurement of the initial 6 months after device implant. FI (Optivol; Medtronic Inc, MN) is a previously described and validated parameter\textsuperscript{18} derived from intrathoracic impedance measurements taken from the right ventricular coil to the pulse generator that were extracted from routine device interrogations.

### Statistical Analysis

Device diagnostic data from the first 6 months of follow-up were used to categorize the subjects as positive or negative of all 6 diagnostic parameters. Mortality was evaluated using follow-up data from RAFT. Data collected at baseline and follow-up were used in the calculation of the MAGGIC score. Ejection fraction, age, height, sex, current smoker, diabetes mellitus, and diagnosis of chronic obstructive lung disease were evaluated at baseline. The most recent value available during the first 6 months of follow-up was used for systolic blood pressure, weight, creatinine, New York Heart Association class, and medication status. All the subjects had a first diagnosis of HF >18 months. Height measurements required for calculation of the body mass index were missing for 130 subjects. These missing data were imputed using the median height by sex from RAFT to calculate body mass index.

Univariable and multivariable hazard ratios (HRs) along with the 95% CIs were estimated using a Cox proportional hazards model. A test of proportionality was performed for the Cox model by adding time-dependent covariates to the model. The time-dependent covariates were generated by creating interactions of the predictor variables and a function of survival time. Activity flag, AF flag, ventricular rate flag, night heart rate flag, shock flag, ventricular pace flag, FI flag, and

| Risk Factor | Addition to Risk Score | Risk Score |
|-------------|------------------------|------------|
| Ejection Fraction (%) | <20 | +7 | 20-24 | +6 | 25-29 | +5 | 30-34 | +3 | 35-39 | +2 | >40 | 0 |
| Extra for age (yrs) | >55 | 56-59 | 60-64 | 65-69 | 70-74 | 75-79 | >80 |
| EF<30 | 0 | +1 | +2 | +4 | +6 | +8 | +10 |
| EF 30 – 39 | 0 | +2 | +4 | +6 | +8 | +10 | +13 |
| EF>40 | 0 | +3 | +5 | +7 | +9 | +12 | +15 |
| Extra for SBP (mmHg) | <110 | 110-119 | 120-129 | 130-139 | 140-149 | >150 |
| +5 | +4 | +3 | +2 | +1 | 0 |
| BMI (kg/m\(^2\)) | <15 | 15-19 | 20-24 | 25-29 | >30 | 0 |
| +6 | +5 | +3 | +2 | +1 |
| Creatinine (μmol/L) | <90 | 90-109 | 110-129 | 130-149 | 150-169 | 170-209 | 210-249 | >250 |
| 0 | +1 | +2 | +3 | +4 | +5 | +6 | +8 |
| NYHA Class | 1 | 2 | 3 | 4 | +1 |
| Male | +1 |
| Current smoker | +1 |
| Diabetic | +3 |
| COPD | +2 |
| First diagnosis of HF in past 18 months | +2 |
| Not on beta-blocker | +3 |
| Not on ACEI/ARB | +1 |

**Figure 1.** Meta-Analysis Global Group in Chronic Heart Failure score. ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; COPD, chronic obstructive pulmonary disease; EF, ejection fraction; HF, heart failure; NYHA, New York Heart Association; SBP, systolic blood pressure. Reprinted from Pocock et al\textsuperscript{4} with permission. Copyright ©2013, Oxford University Press.
Device Diagnostics for HF Prediction  
Manlucu et al

**Table 1.** Baseline Characteristics

| Characteristics                             | All (n=1036) | CRT-D (n=738) | ICD (n=298) |
|---------------------------------------------|--------------|---------------|-------------|
| Age, mean (SD), y                           | 66 (9)       | 66 (9)        | 66 (9)      |
| Male sex                                    | 854 (82)     | 620 (84)      | 234 (79)    |
| Current smoker                               | 128 (12)     | 88 (12)       | 40 (13)     |
| NYHA class                                   |              |               |             |
| II                                          | 952 (92)     | 654 (89)      | 298 (100)   |
| III                                         | 84 (8)       | 84 (11)       | 0 (0)       |
| Ischemic                                    | 661 (64)     | 488 (66)      | 173 (58)    |
| Chronic obstructive lung disease            | 80 (8)       | 60 (8)        | 20 (7)      |
| Hypertension                                | 458 (52)     | 313 (50)      | 145 (58)    |
| Diabetes mellitus                           | 349 (34)     | 236 (32)      | 113 (38)    |
| Left ventricular ejection fraction, mean (SD), % | 23 (5)       | 23 (5)        | 23 (5)      |
| Systolic BP, mean (SD), mm Hg               | 119 (18)     | 118 (17)      | 121 (17)    |
| Creatinine, mean (SD), μmol/L               | 111 (47)     | 111 (47)      | 109 (49)    |
| Body mass index, mean (SD), kg/m²           | 28 (6)       | 28 (6)        | 28 (5)      |
| Baseline medications                        |              |               |             |
| ACE inhibitor                                | 817 (79)     | 588 (80)      | 229 (77)    |
| ARB                                         | 231 (22)     | 161 (22)      | 70 (23)     |
| β-Blockers                                  | 945 (91)     | 675 (91)      | 270 (91)    |

Data are given as number (percentage), unless otherwise indicated. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; CRT-D, cardiac resynchronization therapy defibrillator; ICD, implantable cardioverter-defibrillator; NYHA, New York Heart Association.

MAGGIC score group were included in a multivariable Cox proportional hazards model. Logistic regression models were used to calculate the C-statistic. Kaplan-Meier survival curves were constructed for each group, starting at 6 months postdevice implant. Survival curves were compared using a log-rank test. All analyses were performed using statistical software from SAS, Inc (Version 9.4; Cary, NC). A significance level of 0.05 was used.

**Predictors of Mortality**

Four device diagnostic parameters and MAGGIC score were significant predictors of mortality in a univariable analysis. The HRs for these parameters were as follows: intermediate MAGGIC score versus low MAGGIC score: HR, 2.46; 95% CI, 1.29 to 4.68; \( P=0.006 \); high MAGGIC score versus low MAGGIC score: HR, 6.36; 95% CI, 3.35 to 12.06; \( P<0.001 \); AF flag: HR, 2.38; 95% CI, 1.55 to 3.65; \( P<0.001 \); positive FI: HR, 2.62; 95% CI, 1.81 to 3.79; \( P<0.001 \); activity flag: HR, 2.29; 95% CI, 1.63 to 3.22; \( P<0.001 \); and ICD shock flag: HR, 2.23; 95% CI, 1.40 to 3.55; \( P=0.001 \). In a multivariable analysis, ICD shock dropped off, and the following remained independent predictors of mortality: intermediate to high MAGGIC scores, positive FI, AF flag, and activity flag (Table 2).

A device-integrated diagnostic (DID) parameter was derived to include FI, AF, and activity flags such that patients were considered DID positive (DID+) when FI was positive and either AF flag or activity flag was positive; otherwise, patients

**Results**

**Baseline Patient Characteristics**

Baseline characteristics of the study cohort are summarized in Table 1. Of the 1798 patients enrolled into RAFT, 696 were not implanted with devices capable of the diagnostics required for the analysis and were, therefore, excluded. Another 66 patients were excluded because of insufficient follow-up data and unavailable device and/or laboratory data. A final total of 1036 patients (82% men) with a mean age of 66±9 years were included in the analysis. Most (92%) of patients had mild HF symptoms (New York Heart Association class II) at study enrollment, and the mean left ventricular ejection fraction was moderate to severely impaired at 23±5%. Of the 1036 patients, 738 (71%) were implanted with cardiac resynchronization therapy defibrillator devices. Most patients were on guideline-directed medical therapy; >91% of patients were treated with β-blockers, and >96% were receiving either an angiotensin-converting enzyme inhibitor or an angiotensin-receptor blocker.
Table 2. Multivariable Analysis of Predictors for Mortality

| Variable          | Hazard Ratio (95% CI) | P Value |
|-------------------|-----------------------|---------|
| MAGGIC score      |                       |         |
| 0–16              | ...                   | ...     |
| 17–24             | 2.13 (1.11–4.08)      | <0.001  |
| >24               | 4.61 (2.38–8.93)      | ...     |
| FL                |                       |         |
| FL+               | ...                   | <0.001  |
| FL−               | 2.00 (1.36–2.92)      | ...     |
| AF flag           | 1.70 (1.10–2.64)      | 0.018   |
| Activity flag     | 1.54 (1.08–2.20)      | 0.018   |

There were no significant interaction terms. AF indicates atrial fibrillation; FL, fluid index; FL+, FL positive; FL−, FL negative; MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure.

Table 3. Mortality Stratified According to MAGGIC Score and DID Status

| MAGGIC Score | DID Status | <17 | 17–24 | >24 |
|--------------|------------|-----|-------|-----|
|              | All        | 11  | 58    | 64  |
|              | DID+       | 1   | 11    | 21  |
|              | DID−       | 10  | 47    | 43  |

Data are given as number (percentage) of deaths. DID indicates device-integrated diagnostic; DID+, DID positive; DID−, DID negative; MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure.

Discussion

This study demonstrates the additional prognostic value of implantable DIDs over clinical parameters in the prediction of mortality in intermediate- to high-risk patients with HF. Specifically, a combination of device parameters with a well-validated clinical model, such as MAGGIC, can help to further stratify patients at the highest mortality risk. This observation may have significant implications in an era in which HF remains a lethal pandemic, despite significant strides in medical and device therapy; and identifying patients at highest risk with the highest possible specificity remains an unmet need. Several clinical prediction models have been developed to identify patients who are at highest risk and may need more immediate medical attention. Unfortunately, these models have moderate specificity in identifying high-risk patients and are based on clinical signs and symptoms that often present late in the course of a patient’s illness, which impairs our ability to react in a
timely manner. Thus, better-performing models with capability to reflect patient status on a more dynamic basis are needed to allow for timely intervention in patients with HF. It is well established that widespread use of ICDs, both with and without cardiac resynchronization therapy, has significantly improved survival and functional capacity in the
Figure 4. Kaplan-Meier survival curves in intermediate Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) score (A) and high MAGGIC score (B) groups stratified according to device-integrated diagnostic (DID) positive (DID+) or DID negative (DID−). The combined prognostic value of a positive fluid index plus either an atrial fibrillation or an activity flag is observed in both groups, but most evident in the high-risk cohort.
Device Diagnostics for HF Prediction  Manlucu et al

Modern implantable cardiac devices have the added benefits of sensors, memory, and computing power that have provided a novel and convenient means of monitoring and evaluating patients remotely. Although individual diagnostic parameters may be of marginal value, integration of multiple diagnostic parameters applied in the context of a particular patient’s clinical profile may provide more specific prognostic information.

In this substudy of RAFT, we examined the utility of combining a clinical risk score and DID parameters for prognostication. Among the HF prediction models, we chose the MAGGIC score because it is an easily accessible, commonly used clinical prediction model that was derived in a large, heterogeneous population of almost 40 000 patients with HF and validated in a separate cohort of >51 000 patients. In this analysis, the RAFT cohort was stratified according to MAGGIC score into low-, intermediate-, and high-risk groups. Following multivariable analysis, DID, which accounted for FI, activity, and AF burden, along with intermediate to high MAGGIC scores were identified as independent predictors of increased mortality. When DID was analyzed within the 3 MAGGIC score cohorts, patients with intermediate- and high-risk scores who were also DID+ had a significantly higher 3-year mortality. The discriminating effect of DID on mortality risk was particularly pronounced in the high-risk group, demonstrating a 30% higher mortality rate over the same follow-up period. These data suggest that, when used in conjunction with a clinical prediction model, a combination of device parameters (ie, FI, AF, and activity) can provide powerful incremental prognostic information in patients who are already at particularly high risk of death on the basis of their clinical profile. In this case, the application of this combination of device diagnostics within the clinical context provided by the MAGGIC score may account for the significant difference in predictive power. Not surprisingly, these implantable device diagnostics were not discriminative in the low-risk MAGGIC group given that their mortality rate is already low.

The use of additional clinical risk factors to enhance the predictive power of clinical diagnostic tools is an established and effective means of improving the utility and interpretability of commonly used diagnostic tests. The D-dimer for deep vein thrombosis, high-sensitivity troponin, and the treadmill exercise test for ischemic chest pain are just a few routinely used examples. In our study, the application of the combination of device diagnostics within the clinical context provided by the MAGGIC score helped to further improve overall predictive power. Not surprisingly, these implantable device diagnostics were not discriminative in the low-risk MAGGIC group given that their mortality rate is already low. Nevertheless, the fact that device diagnostic parameters have incremental predictive power on top of a well-developed MAGGIC model based solely on clinical parameters suggests that it may be possible to develop better predictive models by integrating clinical and device parameters into a single model. Furthermore, because device diagnostic data are more dynamic and can now be transmitted via remote monitoring systems, such combined models would also be more responsive and adapt to a particular patient’s changing risk state more readily. We believe that such high-performing and dynamic models are needed to identify patients at highest risk with greater specificity and allow for a timely intervention.

Implantable device diagnostics may improve our ability to identify individuals in need of more immediate intervention. With the advent of remote monitoring technology, these device parameters can be monitored frequently (eg, monthly or biweekly) and alert the need for medical attention without the need for in-person assessment. This has important implications for many patients, especially for those living in remote areas. Therefore, although device-derived data can never fully replace clinical assessment, this technology, especially when combined with clinical data (eg, in an electronic medical record system in which clinical and device data can be merged as inputs to a combined model), may capture the dynamic risk state of the patient more readily. This, in turn, could greatly facilitate more efficient management the patient population with HF, who is rapidly outgrowing the human resources needed to manage them by conventional means.

Limitations

Although the results of this study are promising, it has a few limitations and is susceptible to the usual challenges of any retrospective analysis and unknown confounding variables. For example, although all deaths were adjudicated by a clinical event committee, noncardiac deaths caused by other conditions, such as pneumonia, may still be difficult to differentiate from HF, which can reduce intrathoracic impedance and overestimate the effect of a positive FI and, hence, DID+. Last, although the MAGGIC score has been validated in all patients with HF, including those with preserved ejection fraction, the RAFT cohort was a population that consisted entirely of patients with moderately to severely reduced systolic function (ejection fraction ≤35%). Therefore, the results of this study may not apply to those with HF with preserved ejection fraction.

Conclusions

This study suggests that implantable device diagnostics integrating FI trends, AF burden, and activity level may provide significant incremental prognostic value to clinical prediction scores in intermediate- to high-risk patients with mild to moderate HF. Further prospective studies are needed to validate this finding and determine whether early intervention guided by these measurements can modify risk and decrease mortality.
Sources of Funding
This substudy was supported in part by Medtronic Inc. The primary trial (RAFT [Resynchronization/Defibrillation for Ambulatory Heart Failure Trial]) was supported by the Canadian Institutes of Health Research and Medtronic of Canada.

Disclosures
Dr Manlucu has received honoraria for consulting work and participation on medical advisory boards from Medtronic Inc. As the principal investigator on the original RAFT (Resynchronization/Defibrillation for Ambulatory Heart Failure Trial), Dr Tang received sponsored research support from Medtronic Inc and Medtronic of Canada. Dr Sharma, Dr Warman, and J. Koehler are employees of Medtronic and have received salary, stocks, and stock options from Medtronic. The remaining authors have no disclosures to report.

References
1. Mozaffarian D, Benjamin EM, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER III, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nicholls G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wylie JZ, Woo D, Yeh RW, Turner MB. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:629–682.

2. Roger VL. Epidemiology of heart failure. Circ Res. 2013;113:646–659.

3. Alba AC, Agoritsas T, Jankowski M, Courvoisier D, Walter SD, Guyatt GH, Ross JS. Risk prediction models for mortality in ambulatory patients with heart failure: a systematic review. Circ Heart Fail. 2013;6:881–889.

4. Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Kober L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA, Doughty RN. Predicting survival in heart failure: a risk score based on 59 372 patients from 30 studies. Eur Heart J. 2013;34:1404–1413.

5. Saritpinyu D, Dahlstrom U, Edner M, Lund LH. Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51 043 patients from the Swedish Heart Failure Registry. Eur J Heart Fail. 2014;16:173–179.

6. Small RS, Wickemeyer W, Germany R, Hoppe B, Andruili J, Brady PA, Labeau M, Koehler J, Sarkar S, Hettrick DA, Tang WH. Changes in intrathoracic impedance are associated with subsequent risk of hospitalizations for acute decompensated heart failure: clinical utility of implanted device monitoring without a patient alert. J Card Fail. 2009;15:475–481.

7. Whellan DJ, Usiskin JK, Atwood SM, Pu W, Sarkar S, Porter CB, Pavli BB, O’Connor CM. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF [program to access and review trending information and evaluate correlation to symptoms in patients with heart failure] study. J Am Coll Cardiol. 2010;55:1803–1810.

8. Perego GB, Landolina M, Vergara G, Lunati M, Zanotto G, Pappone A, Lonardi G, Speca G, Iacopino S, Varbaro A, Sarkar S, Hettrick DA, Denaro A. Implantable CRT device diagnostics identify patients with increased risk for heart failure hospitalization. J Interv Card Electrophysiol. 2008;23:235–242.

9. Sharma V, Rathman LD, Small RS, Whellan DJ, Koehler J, Warman E, Abraham WT. Stratifying patients at the risk of heart failure hospitalization using existing device diagnostic thresholds. Heart Lung. 2015;44:129–136.

10. Whellan DJ, Sarkar S, Koehler J, Small RS, Boyle A, Warman EN, Abraham WT. Development of a method to risk stratify patients with heart failure for 30-day readmission using implantable device diagnostics. Am J Cardiol. 2013;111:79–84.

11. Sarkar S, Koehler J. A dynamic risk score to identify increased risk for heart failure decompensation. IEEE Trans Eng Med Biol. 2013;34:147–150.

12. Cowie MR, Sarkar S, Koehler J, Whellan DJ, Crossley GH, Tang WH, Abraham WT, Sharma V, Santini M. Development and validation of an integrated diagnostic algorithm derived from parameters monitored in implantable devices for identifying patients at risk for heart failure hospitalization in an ambulatory setting. Eur Heart J. 2013;34:2472–2480.

13. Gula LJ, Wells GA, Yee R, Koehler J, Sarkar S, Sharma V, Skanes AC, Sapp JI, Redfearn DP, Manlucu J, Tang AS. A novel algorithm to assess risk of heart failure exacerbation using ICD diagnostics: validation from RAFT. Heart Rhythm. 2014;11:1626–1631.

14. Sack S, Wende CM, Nagele H, Katz A, Bauer WR, Carr CS, Malinowski K, Schwacke H, Levy F, Proff J, Berdyshiev S, Paul V. Potential value of automated daily screening of cardiac resynchronization therapy defibrillator diagnostics for prediction of major cardiovascular events: results from Home-CARE (home monitoring in cardiac resynchronization therapy study). Eur J Heart Fail. 2011;13:1019–1027.

15. Tang WH, Warman EN, Johnson JW, Small RS, Heywood JT. Threshold crossing of device-based intrathoracic impedance trends identifies relatively increased mortality risk. Eur Heart J. 2012;33:189–2196.

16. Tang AS, Wells GA, Arnold M, Connolly S, Hohnloser S, Nichol G, Rouleau J, Sheldon R, Talajic M. Resynchronization/defibrillation for ambulatory heart failure trial: rationale and trial design. Curr Opin Cardiol. 2009;24:1–8.

17. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Nichol G, Rozanski A, DeMets D, Redfearn DP, Manlucu J, Tang AS. Combined heart failure device diagnostics identify patients at risk for heart failure hospitalization. IEEE Trans Biomed Eng. 2011;58:1027–1036.

18. Wang L. Fundamentals of intrathoracic impedance monitoring in heart failure. Am J Cardiol. 2007;99:3G–10G.

19. Woo GW, Petersen-Stejskal S, Johnson JW, Conti JB, Aranda JA Jr, Curtis AB. Ventricular reverse remodeling and 6-month outcomes in patients receiving cardiac resynchronization therapy: analysis of the miracle study. J Interv Card Electrophysiol. 2005;12:107–113.

20. St John Sutton M, Ghio S, Plappert T, Tavazzi L, Scelni L, Daubert C, Abraham WT, Gold MR, Hassager C, Herre JM, Linde C; RESynchronization reVerSe remodeling in Systolic left ventricular dysfunction (REVERSE) Study Group. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation. 2009;120:1858–1865.

21. St John Sutton MG, Plappert T, Abraham WT, Smith AL, DeLucirio DB, Leon AR, Loh E, Kocovic DZ, Fisher WG, Ellesat MD, Messenger J, Kruger K, Hilpisch KE, Hill MR; Multicenter InSync Randomized Clinical Evaluation Study Group. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 2003;107:1985–1990.

22. Solomon SD, Foster E, Bourguin M, Shah A, Vlithia E, Brown MW, Hall WJ, Pfeffer MA, Moss AJ; MADIT-CRT Investigators. Effect of cardiac resynchronization therapy on left ventricular systolic dysfunction: a randomized trial. Circulation. 2012;126:95–99.

23. McAlister FA, Ezekowitz J, Hooten N, Vandermeer B, Spoorer C, Dreyden DM, Page RL, Hlatky MA, Rowe BH. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA. 2007;297:2502–2514.

24. Bristow MR, Saxon LA, Bohemer J, Krueger S, Kass DA, De Marco T, Carson P, DeCarlo L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150.